Related Experiment Video
Updated: Feb 13, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Digoxin and Mortality in Patients With Atrial Fibrillation
Renato D Lopes1, Roberto Rordorf2, Gaetano M De Ferrari2
1Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Insights
Digoxin use in atrial fibrillation (AF) patients is linked to increased mortality, especially with higher serum concentrations (≥1.2 ng/ml). Starting digoxin also independently raises death risk, irrespective of heart failure status.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Digoxin is a common medication for managing atrial fibrillation (AF).
- Understanding the risks associated with digoxin use in AF patients is crucial for clinical decision-making.
Purpose of the Study:
- To determine if digoxin use is independently associated with increased mortality in atrial fibrillation (AF) patients.
- To investigate if heart failure or serum digoxin concentration modifies this association.
Main Methods:
- Propensity score-adjusted analysis of 17,897 patients to assess digoxin use and mortality.
- Analysis of new digoxin users versus matched controls.
- Multivariable adjustment to examine serum digoxin concentration and mortality.
Main Results:
- Baseline digoxin use was not linked to increased mortality (aHR: 1.09).
- Serum digoxin concentration ≥1.2 ng/ml was associated with a 56% increased mortality hazard (aHR: 1.56).
- Each 0.5-ng/ml increase in serum digoxin concentration correlated with a 19% higher mortality hazard (p=0.0010).
- New digoxin users showed significantly higher risks of death and sudden death.
Conclusions:
- In AF patients, digoxin use poses an independent mortality risk related to serum concentration, with highest risk at ≥1.2 ng/ml.
- Initiating digoxin is independently associated with increased mortality in AF patients, independent of heart failure.
Background:
Digoxin is widely used in patients with atrial fibrillation (AF).
Objectives:
The goal of this paper was to explore whether digoxin use was independently associated with increased mortality in patients with AF and if the association was modified by heart failure and/or serum digoxin concentration.
Methods:
The association between digoxin use and mortality was assessed in 17,897 patients by using a propensity score-adjusted analysis and in new digoxin users during the trial versus propensity score-matched control participants. The authors investigated the independent association between serum digoxin concentration and mortality after multivariable adjustment.
Results:
At baseline, 5,824 (32.5%) patients were receiving digoxin. Baseline digoxin use was not associated with an increased risk of death (adjusted hazard ratio [HR]: 1.09; 95% confidence interval [CI]: 0.96 to 1.23; p = 0.19). However, patients with a serum digoxin concentration ≥1.2 ng/ml had a 56% increased hazard of mortality (adjusted HR: 1.56; 95% CI: 1.20 to 2.04) compared with those not on digoxin. When analyzed as a continuous variable, serum digoxin concentration was associated with a 19% higher adjusted hazard of death for each 0.5-ng/ml increase (p = 0.0010); these results were similar for patients with and without heart failure. Compared with propensity score-matched control participants, the risk of death (adjusted HR: 1.78; 95% CI: 1.37 to 2.31) and sudden death (adjusted HR: 2.14; 95% CI: 1.11 to 4.12) was significantly higher in new digoxin users.
Conclusions:
In patients with AF taking digoxin, the risk of death was independently related to serum digoxin concentration and was highest in patients with concentrations ≥1.2 ng/ml. Initiating digoxin was independently associated with higher mortality in patients with AF, regardless of heart failure.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Patient-centered Care
Drug Dosing: Geriatric Patients

